Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.66 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.64 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.64 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.64 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436965 | 0.90 | PRMT6 (0.62) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL13498072 | 0.90 | GRIN2B (0.72) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL13588401 | 0.83 | ALDH1A1 (0.73) | — | |
| SCHEMBL13185171 | 0.82 | HTR2A (0.49) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL8302417 | 0.82 | OPRM1 (0.51) | CCR3PRMT6CARM1 | |
| SCHEMBL608270 | 0.82 | GAA (0.48) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL5462238 | 0.82 | KCNH2 (0.73) | KCNH2MGLL | |
| SCHEMBL360084 | 0.82 | KCNH2 (0.77) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL12018067 | 0.81 | CCR3 (0.50) | CCR3PRMT6CARM1PRMT3PRMT1 | |
| SCHEMBL578726 | 0.81 | SLC6A2 (0.52) | CCR3PRMT6CARM1PRMT3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | claimed |
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023144053-A1 | HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023118319-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | disclosed |
| WO-2022258622-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022094435-A1 | MODULATORS OF ORPHAN NUCLEAR RECEPTORS FOR TREATING PANCREATITIS, GLIOBLASTOMA, SARCOPENIA AND STROKE | EMORY UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2021252709-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING, AMELIORATING, AND/OR PREVENTING SIGMA RECEPTOR RELATED DISEASES AND/OR DISORDERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11072632-B2 | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 | UNIVERSITé LAVAL (CA) | 2021-07-27 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| WO-2006103045-A1 | COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2003055478-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-10 | — | — | WO | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0995741-A1 | REMEDIES/PREVENTIVES FOR FREQUENT URINATION/URINARY INCONTINENCE AND TROPONE DERIVATIVES | Nippon Kayaku Kabushiki Kaisha (JP) | 2000-04-26 | — | — | EP | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | CCR3 700/4885PRMT6 2681/4885CARM1 4389/4885 |
| US-11072632-B2 | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 | HSD17B11, HSD17B3, HSD17B1 | CCR3 606/4885PRMT6 3174/4885CARM1 2277/4885 |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | PRMT5, PRMT1, PRMT3 | CCR3 2851/4885PRMT6 4/4885CARM1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.